Skip to main content
. 2022 Mar 17;64:151–158. doi: 10.1016/j.breast.2022.03.001

Table 5.

Overall survival of SafeHER (ITT population) and by timing of chemotherapy.

Overall survival Patients with events, n (%) Event-free rate at 5 years (95% CI)
Overall population, N = 2573 2395 (93.1) 93.5% (92.4%– 94.4%)
No chemotherapy, n = 235 12 (5.1) 95.5% (91.5%–97.6%)
Concurrent chemotherapy, n = 1533 98 (6.4) 94.4% (93.0%–95.5%)
Sequential chemotherapy, n = 805 68 (8.4) 91.2% (88.9%–93.1%)

ITT, intent-to-treat.